Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BACCHUS: Neoadjuvant FOLFOX/Bevacizumab vs FOLFOXIRI/Bevacizumab in High-Risk Rectal Cancer
NCT01650428Phase 2Completed
- Sponsor
- University College London
- Start
- Apr 2013
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in rectal cancer, sponsored by University College London. Started Apr 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01650428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01650428.